Tiger Biosciences
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tiger Biosciences sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Tiger Biosciences: 4 sponsored US clinical trials, 2 recruiting.
Tiger Biosciences sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ulcer, with 2 trials.
Upper-quartile sponsor footprint
Tiger Biosciences sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers
NCT06999590
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.
NCT06826339
Post Market Clinical Experience Study of Sientra 207 Breast Implants
NCT02905617
Sientra Sponsored Silimed Gel-Filled Breast Implant Core Clinical Study
NCT00905645
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 2 |
Therapeutic Areas
Where Tiger Biosciences enrollment is open (later-stage tilt)
2 recruiting of 4 indexed (50% open); 1 completed (25%).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Ulcer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tiger Biosciences: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Tiger Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Tiger Biosciences page
4 registered trials is a research-attention snapshot, not an endorsement of Tiger Biosciences or any single study.
- 2 of Tiger Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ulcer is the condition Tiger Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ulcer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tiger Biosciences pipeline card: 4 registered trials from official public datasets.Report a data error.